Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT05920356
Ignite Creation Date: 2024-05-06 @ 7:11 PM
Last Modification Date: 2024-10-26 @ 3:01 PM
Study NCT ID: NCT05920356
Protocol Section: NCT05920356
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIBC Nonsquamous Non-Small Cell Lung Cancers CodeBreaK 202
Official Title: A Phase 3 Multicenter Randomized Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIBC Nonsquamous Non-Small Cell Lung Cancers Negative for PD-L1 and Positive for KRAS pG12C CodeBreaK 202
Acronym: None
Organization: Amgen
Organization Class: INDUSTRY
Organization Study ID: 20190341
Secondary IDs
Secondary ID Type Domain Link
2022-501863-41 EUDRACT_NUMBER None None
Start Status Module Data
Status Verified Date: 2024-10
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Amgen
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Amgen
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload